Document:

Exhibit 10.3

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

AMERICAN INTERNATIONAL HOLDINGS CORP.

 

	 	Initial
Exercise Price: __________
	 	 
	Warrant
    Shares: _________	Initial
    Exercise Date: June 24, 2021

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________________, or its assigns (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,
to subscribe for and purchase from American International Holdings Corp., a Nevada corporation (the “Company”), shares of
Common Stock as follows:

 

(i)
up to ________ shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”) at any time on or after June
24, 2021 (the “Initial Exercise Date”) and on or prior to the close of business on the five-year anniversary of the
Initial Exercise Date (the “Termination Date”) but not thereafter; and

 

(ii)
The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Agreement”), dated June 24, 2021, between the Company and the Holder.

 

    	1

     

    

 

Section
2. Exercise.

 

(a)
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly
executed facsimile copy of the Notice of Exercise Form annexed hereto. Within the earlier of (i) two Trading Days following the date
of exercise as aforesaid or (ii) the Standard Settlement Period, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. In the event that the Holder is
required to make any payments to the Company’s stock transfer agent in connection with its exercise of this Warrant resulting from
any failure or alleged failure of the Company to pay the transfer agent, the Holder may deduct such sums it pays the transfer agent from
the total Exercise Price due. Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and
receive a replacement Warrant from, the Company), the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within five Trading Days of the date the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one Trading
Day of delivery of such notice. The Holder by acceptance of this Warrant, acknowledges and agrees that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

(b)
Exercise Price. The initial exercise price per share of the Common Stock under this Warrant shall be equal to $_____ per share,
subject to adjustment under Section 3 (the “Exercise Price”).

 

    	2

     

    

 

(c)
Cashless Exercise. If at any time after the six months anniversary of the Initial Exercise Date, there is no effective Registration
Statement covering the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at the Holder’s election,
in whole or in part and in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such
time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the number obtained by dividing [(A x B) – (A x C)] by (D), where:

 

	 	(A)
    =	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise;
	 	 	 
	 	(B)
    =	the
    greater of (i) the arithmetic average of the VWAPs for the five consecutive Trading Days ending on the date immediately preceding
    the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable
    Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which the Holder makes such “cashless
    exercise” election;
	 	 	 
	 	(C)
    =	the
    Exercise Price of this Warrant, as adjusted hereunder, at the time of such exercise; and
	 	 	 
	 	(D)
    =	the
    lesser of (i) the arithmetic average of the VWAPs for the five consecutive Trading Days ending on the date immediately preceding
    the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable
    Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which the Holder makes such “cashless
    exercise” election.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants
being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to
this Section 2(c).

 

For
avoidance of doubt, the phrase “effective Registration Statement” means (i) a Registration Statement covering the sale of
the Warrant Shares has been declared effective by the SEC, has not been withdrawn and is not subject to a stop order issued by the SEC,
and (ii) the Prospectus contained in the Registration Statement complies with Sections 5(b) and 10 of the Securities Act.

 

Notwithstanding
anything herein to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective
Registration Statement covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised via
cashless exercise pursuant to this Section 2(c).

 

    	3

     

    

 

(d)
Mechanics of Exercise.

 

(i)
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted to the Holder by the
Transfer Agent by crediting the account of the Holder’s prime broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (“DWAC”) if the Company is then a participant in such system and (A) there is an effective Registration
Statement covering the sale of the Warrant Shares by the Holder, or (B) or (B) this Warrant is being exercised via cashless exercise
and Rule 144 under the Securities Act is available or otherwise by physical delivery to the address specified by the Holder in the Notice
of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B)
payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such date, the “Warrant
Share Delivery Date”). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to
be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised, with payment to the Company of the Exercise Price (unless by cashless exercise, if permitted) and all taxes required to be
paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid. The Company understands
that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to the Holder.
As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for
late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per
Trading Day after the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant Shares for
which this Warrant is exercised (based on the Exercise Price) which are not timely delivered. The Company shall pay any payment incurred
under this Section 2(d)(i) in immediately available funds upon demand. Furthermore, in addition to any other remedies which may be available
to the Holder, in the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery
Date, the Holder may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon
the Company and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion
of this Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission
is given to the Company or the date the Warrant Shares are delivered to the Holder, whichever date is earlier.

 

(ii)
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be identical to this Warrant.

 

(iii)
Rescission Rights. If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a
certificate or the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then
the Holder will have the right, at any time prior to issuance of such Warrant Shares, to rescind such exercise.

 

    	4

     

    

 

(iv)
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder a certificate or
the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if
any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to
the Holder in connection with the exercise at issue by (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)
of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon written request of the Company, evidence of the
amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.

 

(v)
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

(vi)
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate including any charges (limited to $100 per
issuance) of any clearing firm, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in
the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event
certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise.

 

(vii)
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

    	5

     

    

 

(e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to this Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this
Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without
limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this
Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation
is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in
accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the SEC,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder’s
Warrant at any time, which decrease shall be effectively immediately upon delivery of notice to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant.

 

    	6

     

    

 

Section
3. Certain Adjustments.

 

(a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant or pursuant to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares,
or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such
that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

(b)
Adjustments for Issuance of Additional Securities. If the Company at any time while this Warrant or the Notes are outstanding,
issues or sells any additional shares of Common Stock or Common Stock Equivalents (hereafter defined) (“Additional Shares of Common
Stock”) in a transaction other than an Exempt Issuance, at a price per share less than the Exercise Price then in effect or without
consideration (a “Dilutive Issuance” based on a “Dilutive Issuance Price”), then the Exercise Price upon each
such issuance shall be reduced to the lower of (i) an amount equal to the Dilutive Issuance Price, or (ii) the VWAP on the next Trading
Day following the first public disclosure of the Dilutive Issuance. For the purposes of this Section 3(b), the next Trading Day if an
announcement is made before 4:00 pm New York, NY time is either the day of the announcement or the following Trading Day.

 

Provided,
however, that this Section 3(b) shall not apply if the Common Stock is listed on a Principal Market which is any of the NYSE,
the NYSE American, or the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select.

 

    	7

     

    

 

In
case any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company, together comprising
one integrated transaction, (x) the Common Stock Equivalents (except for indebtedness) will be deemed to have been issued for the par
value of the Common Stock and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been issued
or sold for the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by the Company
pursuant to the terms of such other securities of the Company, less (II) the par value. Any indebtedness shall be valued at the principal
less any original issue discount. If multiple shares of Common Stock are contained in a unit, the aggregate consideration shall be divided
by the number of shares of Common Stock in a unit. If any shares of Common Stock or Common Stock Equivalents are issued or sold or deemed
to have been issued or sold for cash, the amount of such consideration received by the Company will be deemed to be the net amount received
by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued or sold for a consideration other than
cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where such consideration
consists of publicly traded securities, in which case the amount of consideration received by the Company will be the VWAP of such public
traded securities on the date of receipt. If any shares of Common Stock or Common Stock Equivalents are issued to the owners of the non-surviving
entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed
to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of
Common Stock or Common Stock Equivalents, as the case may be.

 

“Common
Stock Equivalents” means any securities of the Company or its Subsidiaries which would entitle the holder thereof to acquire at
any time Common Stock, including, without limitation, any indebtedness, preferred stock, right, option, warrant or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

The
provisions of this Section 3(b) shall apply each time the Company, at any time after the Initial Exercise Date and while this Warrant
or the Note is outstanding, shall issue any securities with a Dilutive Issuance Price. Notwithstanding the foregoing, no adjustment shall
be made pursuant to this Section 3(b) with respect to an Exempt Issuance (as defined in the Agreement).

 

(c)
Adjustment upon Event of Default. Upon the occurrence and during the continuance of an Event of Default (as defined in the Note),
the Holder may, at the Holder’s option, elect to reduce the Exercise Price to the Alternate Conversion Price (as defined in the
Note). Such election by the Holder [shall/shall not] remain in effect upon the Company’s cure of such Event of Default [provided,
however, that any exercise of this Warrant at the Alternate Conversion Price during the continuance of such Event of Default shall continue
to apply after the occurrence of such Event of Default through and including the date of such cure of such Event of Default]. The Company
shall give the Holder prompt written notice of the occurrence of an Event of Default.

 

(d)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent
that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
Notwithstanding the foregoing, no Purchase Rights will be made under this Section 3(d) in respect of an Exempt Issuance.

 

    	8

     

    

 

(e)
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common
Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned
above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date
of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined
by the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the
portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned
above.

 

(f)
Fundamental Transaction.

 

(i)
If, at any time while this Warrant is outstanding the Company enters into a Fundamental Transaction (as defined in the Note), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the exercise
of this Warrant), at the option of the Holder the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant). For purposes of
any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. The Company shall not effect a Fundamental Transaction unless
it gives the Holder at least 10 Trading Days’ prior notice together with sufficient details so the Holder can make an informed
decision as to whether it elects to accept the Alternative Consideration. Within two Trading Days after the Holder has been given such
notice, the Company shall file a Form 8-K disclosing all material information about the Fundamental Transaction which has been given
to the Holder.

 

    	9

     

    

 

(ii)
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction where the Company or its Successor does not remain
a publicly-traded company, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at
any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the
Holder by paying to the Holder an amount of cash equal to the greater of: (i) the Black Scholes Value of the remaining unexercised portion
of this Warrant on the date of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per
share paid in such Fundamental Transaction minus the then in effect Exercise Price. “Black Scholes Value” means the value
of the unexercised portion of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function
on Bloomberg L.P. determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting
(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public announcement of
the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per
share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date.

 

(iii)
If Section 3(f)(i) is not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant prior to such Fundamental Transaction (without regard to any limitation on the exercise
of this Warrant), and with an exercise price which applies the then-current Exercise Price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the
same effect as if such Successor Entity had been named as the Company herein.

 

    	10

     

    

 

Notwithstanding
the foregoing, no adjustment shall be made pursuant to this Section 3(f) with respect to an Exempt Issuance (as defined in the Agreement).

 

(g)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(h)
Notice to Holder.

 

(i)
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the
number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address
to the Company and change such address.

 

(ii)
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall deliver to the Holder at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days’ prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not
to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record
shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to email such notice or any defect therein
or in the emailing thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent
that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries
(as determined in good faith by the Company), the Company shall simultaneously file such notice with the SEC pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    	11

     

    

 

Section
4. Transfer of Warrant.

 

(a)
Transferability. Subject to compliance with any applicable securities laws and the provisions of the Agreement, this Warrant and
all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of
this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.

 

(b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

(c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for
all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof other than as explicitly set forth in Section 3.

 

    	12

     

    

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant
or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. In no event shall
the Holder be required to post a bond or other security.

 

(c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.

 

(d)
Authorized Shares.

 

The
Company covenants that during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock,
free of preemptive rights three times the number of shares of Common Stock issuable upon exercise of this Warrant, subject to adjustment
pursuant to Section 3. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares
upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to
assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of any Principal Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

In
addition to any other remedies provided by this Warrant or the Agreement, if the Company at any time fails to meet this reservation of
Common Stock requirement within 45 days after written notice from the Holder, it shall pay the Holder as partial liquidated damages and
not as a penalty a sum equal to $500 per day for each $100,000 of such Holder’s Subscription Amount (or the Subscription Amount
of the original Purchaser). The Company shall not enter into any agreement or file any amendment to its Articles of Incorporation (including
the filing of a Certificate of Designation) which conflicts with this Section 5(d) while the Notes (as defined in the Agreement) and
Warrants remain outstanding.

 

Except
and to the extent waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its Certificate of Incorporation (or charter) or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)
use best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    	13

     

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

(e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Agreement.

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or
if not exercised on a cashless basis when Rule 144 is available, will have restrictions upon resale imposed by state and federal securities
laws.

 

(g)
Non-waiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant or the other Transaction Documents, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

(h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Agreement.

 

(i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

(j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate or that there is no irreparable harm
and not to require the posting of a bond or other security.

 

    	14

     

    

 

(k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by any Holder from time to time of this Warrant or any Warrant Shares.

 

(l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.

 

(m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

 

(n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

(o)
Most Favored Nations. From the Initial Exercise Date until the Termination Date, in the event that the Company issues or sells
any shares of Common Stock, any securities of the Company which would entitle the holder of such securities to acquire at any time Common
Stock, including, without limitation, any preferred stock, Convertible Securities, rights, Options, warrants, or other debt or equity
instrument that is at any time convertible into, exercisable for, or exchangeable for, or otherwise entitles the holder to receive Common
Stock, the Company shall provide notice to the Holder of such issuance and, if the Holder reasonably believes that any of the terms and
conditions are more favorable to such investors than the terms and conditions of this Warrant, upon notice to the Company, the Company
shall within five Trading Days amend the terms of this Warrant to give the Holder the benefit of the more favorable terms and conditions.
The Holder shall be entitled to rely upon the Company’s representations and warranties set forth in any agreement containing the
more favorable terms and conditions.

 

********************

 

(Signature
Page Follows)

 

    	15

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	AMERICAN
    INTERNATIONAL HOLDINGS CORP.
	 	 	 
	 	By:	 
	 	Name:
    	Jacob
    Cohen
	 	Title:	President
    and CEO

 

Acknowledged
and accepted by:

 

 HOLDER:

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    	16

     

    

 

NOTICE
OF EXERCISE

 

	TO:	AMERICAN
    INTERNATIONAL HOLDINGS CORP.

 

(1)
The undersigned hereby elects to purchase _____________Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ] in lawful money of the United States; or

 

[  ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

___________________________________

 

(4)
After giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

___________________________________

 

___________________________________

 

___________________________________

 

 

SIGNATURE
OF HOLDER

 

Name
of Investing Entity: __________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: ____________________________________________________

Name
of Authorized Signatory: ______________________________________________________________________

Title
of Authorized Signatory: _______________________________________________________________________

Date: _________________________________________________________________________________________

 

    	17

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

AMERICAN
INTERNATIONAL HOLDINGS CORP.

 

FOR
VALUE RECEIVED,_____all of or________shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

_________________________________________________whose
address is

 

_______________________________________________________________

 

_______________________________________________________________

  

	 	 	Dated:_______________,________	 
	 	 	 	 
	 	Holder’s
    Signature:	 	 
	 	 	 	 
	 	Holder’s
    Address:	 	 
	 	 	 	 
	 	 	 	 

 

Signature
Guaranteed: ____________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

    	18Exhibit
10.4

 

REGISTRATION
RIGHTS AGREEMENT

 

THIS
REGISTRATION RIGHTS AGREEMENT is dated as of June 24, 2021 (the “Execution Date”), by and between American International
Holdings Corp., a Nevada corporation (the “Company”), and the Person identified as an investor on the signature page
hereto (together with its respective successors and assigns, the “Investor”).

 

WHEREAS,
the Company has agreed to provide certain registration rights to the Investor in order to induce the Investor to enter into that certain
Securities Purchase Agreement by and between the Company and the Investor dated as of June 24, 2021 (the “Purchase Agreement”).

 

Now,
therefore, in consideration of the mutual promises and the covenants as set forth herein, the parties hereto hereby agree as follows:

 

1.
Definitions. Unless the context otherwise requires, capitalized terms used herein without definition and defined in the
Purchase Agreement are used herein as defined therein. Notwithstanding the foregoing, as used herein the capitalized words and terms
defined in this Section 1 shall have the meanings herein specified for all purposes of this Agreement, applicable to both the
singular and plural forms of any of the terms herein defined:

 

“Agreement”
means this Registration Rights Agreement, as the same may be amended, modified or supplemented in accordance with the terms hereof.

 

“Board”
means the board of directors of the Company.

 

“Common
Stock” means the Company’s authorized common stock, as constituted on the date of this Agreement, any stock into which
such Common Stock may thereafter be changed and any stock of the Company of any other class, which is not preferred as to dividends or
assets over any other class of stock of the Company and which is not subject to redemption, issued to the holders of shares of such Common
Stock upon any re-classification thereof.

 

“Company”
has the meaning assigned to it in the introductory paragraph of this Agreement.

 

“Company
Securities” means any securities proposed to be sold by the Company for its own account in a registered public offering.

 

“Exchange
Act” means the Securities Exchange Act of 1934 (or successor statute).

 

“Excluded
Forms” means registration statements under the Securities Act on Forms S-4 and S-8 or any successors thereto and any form used
in connection with an initial public offering of securities.

 

“Investor”
has the meaning assigned to it in the introductory paragraph of this Agreement.

 

“Person”
includes any natural person, corporation, trust, association, company, partnership, joint venture, limited liability company and other
entity and any government, governmental agency, instrumentality or political subdivision.

 

    	1

     

    

 

“Purchase
Agreement” has the meaning assigned to it in the introductory paragraph of this Agreement.

 

“Register”
“registered” and “registration” refer to a registration effected by preparing and filing a registration
statement on other than any of the Excluded Forms in compliance with the Securities Act, and the declaration or ordering of the effectiveness
of such registration statement.

 

“Registrable
Securities” means (i) the Common Stock to be acquired by the Investor pursuant to the conversion of the Note and exercise of
the Warrants issued under the Purchase Agreement and any other shares of Common Stock subsequently acquired by the Investor, and (ii)
any securities of the Company issued with respect to such Common Stock by way of any stock dividend or stock split or in connection with
any merger, combination, recapitalization, share exchange, consolidation, reorganization or other similar transaction.

 

“Representatives”
means all shareholders, officers, directors, members, managers, partners, employees and agents.

 

“Rule
144” has the meaning assigned to it in Section 8 of this Agreement.

 

“SEC”
means the Securities and Exchange Commission or any other governmental body at the time administering the Securities Act.

 

“Securities
Act” means the Securities Act of 1933 (or successor statute).

 

“Selling
Expenses” means all selling commissions, finder’s fees and stock transfer taxes applicable to the Registrable Securities
registered by the Investor and all fees and disbursements of counsel for the Investor.

 

2.
Required Registration. Within 21 days after the Execution Date, the Company shall file with the SEC a registration statement
on Form S-1 or a successor form covering the public offering and sale of all of the Registrable Securities. The failure to file the registration
statement required by the preceding sentence shall constitute an Event of Default under the Note.

 

3.
Piggyback Registration.

 

(a)
In addition to and not in limitation of the other registration rights of the Investor under this Agreement, each time the Company proposes
for any reason to register any of its Common Stock or other Company Securities under the Securities Act in connection with the proposed
offer and sale of its Common Stock for money for its own account and/or for stockholders of the Company for their accounts (the “Proposed
Registration”), other than pursuant to a registration statement on Excluded Forms, the Company shall promptly give written
notice of such Proposed Registration to the Investor and hereby irrevocably grants to the Investor the right to include its Registrable
Securities in the Proposed Registration. Such notice shall describe the amount and type of securities to be included in the Proposed
Registration, the intended method(s) of distribution and the name of the proposed managing underwriters, if any.

 

    	2

     

    

 

(b)
The Investor shall have 30 days from the receipt of such notice to deliver to the Company a written request specifying the number of
shares of the Registrable Securities the Investor intends to sell in the Proposed Registration and the Investor’s intended method
of disposition.

 

(c)
In the event that the Proposed Registration by the Company is, in whole or in part, an underwritten public offering, the Company shall
so advise the Investor as part of the written notice given pursuant to Section 2(a), and any request under Section 2(b) must specify
that the Investor’s Registrable Securities be included in the underwriting on the same terms and conditions as the shares of Common
Stock, if any, otherwise being sold through underwriters under such registration.

 

(d)
Upon receipt of a written request pursuant to Section 2(b), the Company shall promptly cause all such shares of Registrable Securities
held by the Investor to be registered under the Securities Act (and included in any related qualifications under blue sky laws or other
compliance), to the extent required to permit sale or disposition as set forth in the Proposed Registration.

 

(e)
In the event that the offering is to be an underwritten offering, if the Investor proposes to distribute its shares of Registrable Securities
through such underwritten offering, then, the Investor agrees to enter into an underwriting agreement with the underwriter or underwriters
selected for such underwriting by the Company, provided that such underwriting agreement contains customary terms and provisions and
all other holders proposing to sell shares of Common Stock in the Proposed Registration enter into a substantially similar underwriting
agreement with such underwriter(s).

 

4.
Obligations of the Company. If and whenever the Company is required by the provisions hereof to effect or cause the registration
of any Registrable Securities under the Securities Act as provided herein, the Company shall:

 

(a)
use commercially reasonable efforts to prepare and file with the SEC a registration statement with respect to such Registrable Securities
and use commercially reasonable efforts to cause such registration statement to become effective (and to remain effective (provided that
before filing a registration statement or any amendment or supplement thereto, the Company will furnish to the Investor copies of the
documents proposed to be filed)); 

 

(b)
use commercially reasonable efforts to prepare and file with the SEC such amendments to such registration statement (including post-effective
amendments) and supplements to the prospectus included therein as may be necessary to keep such registration statement effective, subject
to the qualifications in Section 4(a), and to comply with the provisions of the Securities Act with respect to the sale or other disposition
of all Registrable Securities covered by such registration statement during such period in accordance with the intended methods of disposition
by the Investor set forth in such registration statement;

 

    	3

     

    

 

(c)
furnish to the Investor such number of copies of such registration statement and of each such amendment and supplement thereto (in each
case including all exhibits), such number of copies of the prospectus included in such registration statement (including each preliminary
prospectus), in conformity with the requirements of the Securities Act, and such other documents, as the Investor may reasonably request,
in order to facilitate the public sale or other disposition of the Registrable Securities owned by the Investor;

 

(d)
use all commercially reasonable efforts to make such filings under the securities or blue sky laws of such jurisdictions as the Investor
may reasonably request to enable the Investor to consummate the sale in such state or jurisdiction of the Registrable Securities owned
by the Investor;

 

(e)
notify the Investor at any time when a prospectus relating to their Registrable Securities is required to be delivered under the Securities
Act, of the Company’s becoming aware that the prospectus included in the related registration statement, as then in effect, includes
an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances then existing, and promptly prepare and furnish to the Investor a reasonable number
of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities,
such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the circumstances then existing;

 

(f)
otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC and to perform its obligations
hereunder;

 

(g)
use commercially reasonable efforts to cause the Registrable Securities to be quoted on each trading market and/or in each quotation
service on which the Common Stock of the Company is then quoted; 

 

(h)
provide a transfer agent for all Registrable Securities and promptly pay all fees and costs of the transfer agent;

 

(i)
provide a CUSIP number for all Registrable Securities, in each case not later than the effective date of the applicable registration
statement; and

 

(j)
notify the Investor of any stop order threatened or issued by the SEC and take all actions reasonably necessary to prevent the entry
of such stop order or to remove it if entered. 

 

5.
Other Procedures.

 

(a)
Subject to the remaining provisions of this Section 5(a) and the Company’s general obligation to use commercially reasonable efforts
under Section 4, the Company shall be required to maintain the effectiveness of a registration statement until the earlier of (i) the
sale of all Registrable Securities, or (ii) when all Registrable Securities held by the Investor are eligible to be sold without volume
limits or other limitations under Rule 144 (or successor rules). Provided, however, if the Company was ever a shell issuer as defined
by Rule 144, the Company shall maintain the effectiveness of the registration statement for a period of two years from the date of this
Agreement. The Company shall have no liability to the Investor for delays in the Investor being able to sell the Registrable Securities
as long as the Company uses commercially reasonable efforts to file a registration statement, amendments to a registration statement,
post-effective amendments to a registration statement or supplements to a prospectus contained in a registration statement (including
any amendment or post effective amendments).

 

    	4

     

    

 

(b)
In consideration of the Company’s obligations under this Agreement, the Investor agree that, upon receipt of any notice from the
Company of the happening of any event of the kind described in Section 4(e) herein, the Investor shall forthwith discontinue his sale
of Registrable Securities pursuant to the registration statement covering such Registrable Securities until the Investor’s receipt
of the copies of the supplemented or amended prospectus contemplated by said Section 4(e) and, if so directed by the Company, shall deliver
to the Company (at the Company’s expense) all copies, other than permanent file copies, then in the Investor’s possession
of the prospectus covering such Registrable Securities current at the time of receipt of such notice.

 

(c)
The Company’s obligation to file any registration statement or amendment including a post-effective amendment, shall be subject
to the Investor, as applicable, furnishing to the Company in writing such information and documents regarding the Investor and the distribution
of the Investor’s Registrable Securities as may reasonably be required to be disclosed in the registration statement in question
by the rules and regulations under the Securities Act or under any other applicable securities or blue sky laws of the jurisdiction referred
to in Section 4(d) herein. The Company’s obligations are also subject to the Investor promptly executing any representation letter
concerning compliance with Regulation M under the Exchange Act (or any successor rule or regulation). If the Investor fails to provide
all of the information required by this Section 5(c), the Company shall have no obligation to include his Registrable Securities in a
registration statement or it may withdraw the Investor’s Registrable Securities from the registration statement without incurring
any penalty or otherwise incurring liability to the Investor.

 

(d)
If any such registration or comparable statement refers to the Investor by name or otherwise as a stockholder of the Company, but such
reference to the Investor by name or otherwise is not required by the Securities Act or the rules thereunder, then the Investor shall
have the right to require the deletion of the reference to the Investor, as may be applicable.

 

(e)
In connection with the sale of Registrable Securities, the Investor shall deliver to each purchaser a copy of any necessary prospectus
and, if applicable, prospectus supplement, within the time required by Section 5(b) of the Securities Act.

 

6.
Registration Expenses. In
connection with any registration of Registrable Securities pursuant to Sections 2 or 3, the Company shall, whether or not any such registration
shall become effective, from time to time, pay all expenses (other than Selling Expenses) incident to its performance of or compliance,
including, without limitation, all registration, and filing fees, fees and expenses of compliance with securities or blue sky laws, word
processing, printing and copying expenses, messenger and delivery expenses, fees and disbursements of counsel for the Company and all
independent public accountants and other Persons retained by the Company.

 

    	5

     

    

 

7.
Indemnification.

 

(a)
In the event of any registration of any shares of Common Stock under the Securities Act pursuant to this Agreement, the Company shall
indemnify, defend and hold harmless the Investor, its Affiliates, and their respective Representatives, successors and assigns, from
and against any losses, claims, damages or liabilities, joint or several, to which the Investor, its Affiliates, and their respective
Representatives, successors and assigns may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material
fact contained in any registration statement under which such Registrable Securities were registered under the Securities Act, any preliminary
prospectus or final prospectus contained therein, or any amendment or supplement thereto, or any document incident to registration or
qualification of any Registrable Securities pursuant to Section 4(d) herein, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or,
with respect to any prospectus, necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, or any violation by the Company of the Securities Act, the Exchange Act, or state securities or blue sky laws or relating
to action or inaction required of the Company in connection with such registration or qualification under the Securities Act or such
state securities or blue sky laws. If the Company fails to defend the Investor, its Affiliates, and their respective Representatives,
successors and assigns, as applicable, as required by Section 7(c) herein, it shall reimburse (after receipt of appropriate documentation)
the Investor, its Affiliates, and their respective Representatives, successors and assigns for any legal or any other out-of-pocket expenses
reasonably incurred by any of them in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the Company shall not be liable to the Investor, its Affiliates, or their respective Representatives, successors
or assigns in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue
statement or alleged untrue statement or omission or alleged omission made in said registration statement, said preliminary prospectus,
said prospectus, or said amendment or supplement or any document incident to registration or qualification of any Registrable Securities
pursuant to Section 4(d) hereof in reliance upon and in conformity with written information furnished to the Company by the Investor,
its Affiliates, or their respective Representatives, successors or assigns specifically for use in the preparation thereof or (ii) any
act or failure to act of the Investor, its Affiliates, or their respective Representatives, successors or assigns including the failure
of the Investor to deliver a prospectus as required by Section 6(e) of the Securities Act.

 

(b)
In the event of any registration of any Registrable Securities under the Securities Act pursuant to this Agreement, the Investor shall,
severally and not jointly, indemnify and hold harmless (in the same manner and to the same extent as set forth in Section 7(a)) the Company,
each director of the Company, each officer of the Company who signs such registration statement, the Company’s attorneys and auditors
and any Person who controls the Company within the meaning of the Securities Act, from and against any loss, claim, damage or liability
that arises out of or is based upon any untrue statement or omission from such registration statement, any preliminary prospectus or
final prospectus contained therein, or any amendment or supplement thereto, if and to the extent that such untrue statement or omission
was made in reliance upon and in conformity with written information furnished to the Company by the Investor specifically for use in
the preparation of such registration statement, preliminary prospectus, final prospectus or amendment or supplement.

 

    	6

     

    

 

(c)
Promptly after receipt by an indemnified party of notice of the commencement of any action involving a claim referred to in Section 7(a)
or (b), such indemnified party shall, if a claim in respect thereof is made against an indemnifying party, give written notice to such
indemnifying party of the commencement of such action. The indemnifying party shall be relieved of its obligations under this Section
7(c) if and to the extent that the indemnified party delays in giving notice and the indemnifying party is damaged or prejudiced by the
delay. In case any such action is brought against an indemnified party, the indemnifying party shall be entitled to participate in and
to assume the defense thereof, jointly with any other indemnifying party similarly notified to the extent that it may wish, with counsel
reasonably satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election
so as to assume the defense thereof, the indemnifying party shall be responsible for any legal or other expenses subsequently incurred
by the indemnifying party in connection with the defense thereof, provided, however, that, if counsel for an indemnified party
shall have reasonably concluded that there is an actual or potential conflict of interest between the indemnified party and the indemnifying
party, the indemnifying party shall not have the right to assume the defense of such action on behalf of such indemnified party, and
such indemnifying party shall reimburse such indemnified party for the fees and expenses of counsel retained by the indemnified party
which are reasonably related to the matters covered by the indemnity agreement provided in this Section 7; provided, however,
that in no event shall any indemnification by the Investor under this Section 7 exceed the net proceeds from the sale of Registrable
Securities received by the Investor. No indemnified party shall make any settlement of any claims indemnified against hereunder without
the written consent of the indemnifying party, which consent shall not be unreasonably withheld. In the event that any indemnifying party
enters into any settlement without the written consent of the indemnified party, the indemnifying party shall not consent to entry of
any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff
of a release of such indemnified party from all liability in respect to such claim or litigation.

 

(d)
In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which (i) any indemnified
party makes a claim for indemnification pursuant to this Section 7, but it is judicially determined (by the entry of a final judgment
or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case notwithstanding the fact that this Section 7 provides for indemnification in such case,
or (ii) contribution under the Securities Act may be required in circumstances for which indemnification is provided under this Section
7; then, in each such case, the Company and the Investor shall contribute to the aggregate losses, claims, damages or liabilities to
which they may be subject as is appropriate to reflect the relative fault of the Company and the Investor in connection with the statements
or omissions which resulted in such losses, claims, damages or liabilities, it being understood that the parties acknowledge that the
overriding equitable consideration to be given effect in connection with this provision is the ability of one party or the other to correct
the statement or omission (or avoid the conduct or take an act) which resulted in such losses, claims, damages or liabilities, and that
it would not be just and equitable if contribution pursuant hereto were to be determined by pro-rata allocation or by any other method
of allocation which does not take into consideration the foregoing equitable considerations. Notwithstanding the foregoing, (i) no the
Investor shall be required to contribute any amount in excess of the net proceeds to him of all Registrable Securities sold by him pursuant
to such registration statement, and (ii) no Person who is guilty of fraudulent misrepresentation within the meaning of Section 11(f)
of the Securities Act shall be entitled to contribution from any Person who is not guilty of such fraudulent misrepresentation.

 

    	7

     

    

 

(e)
Notwithstanding any of the foregoing, if, in connection with an underwritten public offering of the Registrable Securities, the Company,
the Investor and the underwriters enter into an underwriting agreement relating to such offering which contains provisions covering indemnification
among the parties, then the indemnification provision of this Section 7 shall be deemed inoperative for purposes of such offering.

 

8.
Rule 144. As long as the Investor holds restricted securities (as that term is used in Rule 144) issued by the Company,
the Company covenants that it will (i) make and keep public information available, as those terms are understood and defined in Rule
144, at all times, (ii) file in a timely manner the reports and other documents required to be filed under the Securities Act or the
Exchange Act and the rules and regulations adopted by the SEC thereunder, (iii) furnish to the Investor promptly upon request (x) a written
statement by the Company as to its compliance with the reporting requirements of Rule 144 and the Exchange Act, (y) a copy of the most
recent annual or quarterly report of the Company, and (z) such other information as the Investor may reasonably request, and (iv) cooperate
with the Investor and respond as promptly as possible to any requests from the Investor in connection with Rule 144 transfers of restricted
securities, in each case to enable the Investor to sell his Registrable Securities without registration under the Securities Act within
the limitation of the exemption provided by (a) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or
(b) any similar rule or regulation hereafter adopted by the SEC (collectively, “Rule 144”). Provided, however, nothing contained
in this Section 8 or elsewhere in this Agreement shall prevent the Company from consummating a transaction in which another entity acquires
it through a merger or similar transaction.

 

9.
Severability. In the event any parts of this Agreement are found to be illegal, unenforceable or void, the remaining provisions
of this Agreement shall nevertheless be binding with the same effect as though the illegal, unenforceable or void parts were deleted.

 

10.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but
all of which together shall constitute one and the same instrument. The execution of this Agreement may be by actual or facsimile signature.

 

11.
Benefit. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their legal representatives,
successors and assigns.

 

12.
Notices and Addresses. All notices, approvals, requests, demands and other communications hereunder shall be delivered
or made in the manner set forth in, and shall be effective in accordance with the terms of, the Purchase Agreement.

 

    	8

     

    

 

13.
Attorneys’ Fees. In the event that there is any controversy or claim arising out of or relating to this Agreement,
or to the interpretation, breach or enforcement thereof, and any action or proceeding relating to this Agreement is filed, the prevailing
party shall be entitled to an award by the court of reasonable attorneys’ fees, costs and expenses.

 

14.
Entire Agreement; Oral Evidence. This Agreement constitutes the entire Agreement between the parties and supersedes all
prior oral and written agreements between the parties hereto with respect to the subject matter hereof. Neither this Agreement nor any
provision hereof may be changed, waived, discharged or terminated orally, except by a statement in writing signed by the party or parties
against which enforcement of the change, waiver discharge or termination is sought.

 

15.
Additional Documents. The parties hereto shall execute such additional instruments as may be reasonably required by their
counsel in order to carry out the purpose and intent of this Agreement and to fulfill the obligations of the parties hereunder.

 

16.
Governing Law. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder
whether relating to its execution, its validity, the obligations provided herein or performance shall be governed or interpreted according
to the internal laws of the State of Wyoming. 

 

17.
Section or Paragraph Headings. Section headings herein have been inserted for reference only and shall not be deemed to
limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part any of the terms or provisions of this Agreement.

 

[Signature
Page Follows]

 

    	9

     

    

 

IN
WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed personally or by a duly authorized representative
thereof as of the Execution Date.

 

	 	Company:
	 	 
	 	American
    International Holdings Corp. 
	 	 	                                    
	 	By:
	
	 	Name:
    	Jacob
    D. Cohen
	 	Title:
    	CEO

 

	 	Investor:
	 	
	 	 	 
	 	By:	                            
	 	Name: 	 
	 	Title: 	 

 

[Signature
Page to Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]